Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
Novo Nordisk’s share price fell over 8% on Wednesday after the company reported lower-than-expected sales of Wegovy.
According to the Financial Times, Apple is ramping up its Apple News division. But can it fix its irritating AI hallucinations?
Nvidia, the chipmaking king, has announced a slew of consumer-focused hardware, including a $3,000 “personal AI supercomputer” called Digits.
The Wall Street watchdog is facing criticism from lawmakers, along with two lawsuits, that could theoretically redefine the agency.